Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer
NCT ID NCT04188145
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding bevacizumab (a drug that starves tumors by blocking new blood vessels) to standard maintenance chemotherapy helps people with metastatic colorectal cancer stay progression-free longer. About 400 adults whose disease is controlled after 4–6 months of initial chemotherapy are randomly assigned to receive either fluoropyrimidine alone or fluoropyrimidine plus bevacizumab. The study measures time to treatment failure, including progression or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of fluoropyrimidine chemotherapy (capecitabine or 5-FU) and bevacizumab, a drug that blocks blood vessel growth to tumors
- What this could lead to
- If successful, this could establish a more effective maintenance regimen that keeps metastatic colorectal cancer under control longer after initial chemotherapy.
- What could go wrong
- This is a phase 3 trial, but the benefit may be modest, and adding bevacizumab increases risks like bleeding, high blood pressure, and gastrointestinal perforation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chu Dijon Bourgogne
Dijon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a simpler chemo schedule tame colorectal cancer with fewer side effects?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?